Dexamethasone-mediated changes in adipose triacylglycerol metabolism are exaggerated, not diminished, in the absence of a functional GR dimerization domain

Endocrinology

Volumn 154, Issue 4, 2013, Pages 1528-1539

  Roohk, Donald J ^a   Mascharak, Smita ^b   Khambatta, Cyrus ^a   Leung, Ho ^a   Hellerstein, Marc ^a,c   Harris, Charles ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; INSULIN; MUSCLE PROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIMERIZATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EX VIVO STUDY; FEMALE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ADIPOSE TISSUE; ANIMALS; BONE AND BONES; COLLAGEN; DEXAMETHASONE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCOCORTICOIDS; LIPID METABOLISM; MICE; MICE, TRANSGENIC; MUSCLE PROTEINS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, GLUCOCORTICOID; SKIN; TRIGLYCERIDES;

EID: 84875859581     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1047     Document Type: Article

References (54)

1. Besser GM, Edwards CR. Cushing's syndrome. Clin Endocrinol Metab. 1972;1:451-490.
2. Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol. 1998;82:704-708.
3. Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 1985;318:635-641.
4. Schoneveld OJ, Gaemers IC, Lamers WH. Mechanisms of glucocorticoid signalling. Biochim Biophys Acta. 2004;1680:114-128.
5. Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet. 2005;365:801-803.
6. Rosen J, Miner JN. The search for safer glucocorticoid receptor ligands. Endocr Rev. 2005;26:452-464.
7. Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol. 2007;275:109-117.
8. Giguère V, Hollenberg SM, Rosenfeld MG, Evans RM. Functional domains of the human glucocorticoid receptor. Cell. 1986;46:645-652.
9. Scheinman R, Gualberto A, Jewell C, Cidlowski J, Baldwin A Jr. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol. 1995; 15:943-953.
10. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci U S A. 1994;91: 752-756.
11. Yang-Yen HF, Chambard JC, Sun YL, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell. 1990;62:1205-1215.
12. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol. 1997;11: 1245-1255.
13. Miner JN, Yamamoto KR. The basic region of AP-1 specifies glucocorticoid receptor activity at a composite response element. Genes Dev. 1992;6:2491-2501.
14. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 2000;14: 2314-2329.
15. De Bosscher K. Selective glucocorticoid receptor modulators. J Steroid Biochem Mol Biol. 2010;120:96-104.
16. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23-43.
17. De Bosscher K, Vanden Berghe W, Beck IM, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A. 2005;102:15827-15832.
18. Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol. 2007;275:98-108.
19. Miner JN. Designer glucocorticoids. Biochem Pharmacol. 2002;64: 355-361.
20. Schacke H, Schottelius A, Docke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A. 2004;101:227-232.
21. Heck S, Kullmann M, Gast A, et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 1994;13:4087-4095.
22. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 1998; 93:531-541.
23. Reichardt HM, Tuckermann JP, Gottlicher M, et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 2001;20:7168-7173.
24. Frijters R, Fleuren W, Toonen EJ, et al. Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC Genomics. 11:359.
25. Rauch A, Seitz S, Baschant U, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 11:517-531.
26. Waddell DS, Baehr LM, van den Brandt J, et al. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol. 2008;295:E785-E797.
27. 2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci U S A. 2002;99: 15345-15350.
28. Roohk DJ, Varady KA, Turner SM, et al. Differential in vivo effects on target pathways of a novel arylpyrazole glucocorticoid receptor modulator compared with prednisolone. J Pharmacol Exp Ther. 333:281-289.
29. Collins ML, Eng S, Hoh R, Hellerstein MK. Measurement of mitochondrial DNA synthesis in vivo using a stable isotope-mass spectrometric technique. J Appl Physiol. 2003;94:2203-2211.
30. 2O incorporation into the glycerol moiety and application of MIDA. Am J Physiol Endocrinol Metab. 2003;285:E790-E803.
31. Gardner JL, Turner SM, Bautista A, Lindwall G, Awada M, Hellerstein MK. Measurement of liver collagen synthesis by heavy water labeling: effects of profibrotic toxicants and antifibrotic interventions. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1695-G1705.
32. Busch R, Kim YK, Neese RA, et al. Measurement of protein turnover rates by heavy water labeling of nonessential amino acids. Biochim Biophys Acta. 2006;1760:730-744.
33. Hellerstein MK, Christiansen M, Kaempfer S, et al. Measurement of de novo hepatic lipogenesis in humans using stable isotopes. J Clin Invest. 1991;87:1841-1852.
34. Hellerstein MK, Neese RA, Schwarz JM. Model for measuring absolute rates of hepatic de novo lipogenesis and reesterification of free fatty acids. Am J Physiol. 1993;265:E814-E820.
35. Turner SM, Roy S, Sul HS, et al. Dissociation between adipose tissue fluxes and lipogenic gene expression in ob/ob mice. Am J Physiol. 2007;292:E1101-E1109.
36. Bruss MD, Khambatta CF, Ruby MA, Aggarwal I, Hellerstein MK. Calorie restriction increases fatty acid synthesis and whole body fat oxidation rates. Am J Physiol. 298:E108-E116.
37. Neese RA, Siler SQ, Cesar D, et al. Advances in the stable isotopemass spectrometric measurement of DNA synthesis and cell proliferation. Anal Biochem. 2001;298:189-195.
38. Hellerstein MK, Neese RA. Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations. Am J Physiol. 1999;276:E1146-E1170.
39. Varady KA, Roohk DJ, Hellerstein MK. Dose effects of modified alternate-day fasting regimens on in vivo cell proliferation and plasma insulin-like growth factor-1 in mice. J Appl Physiol. 2007; 103:547-551.
40. Varady KA, Roohk DJ, Loe YC, McEvoy-Hein BK, HellersteinMK. Effects of modified alternate-day fasting regimens on adipocyte size, triglyceride metabolism, and plasma adiponectin levels in mice. J Lipid Res. 2007;48:2212-2219.
41. Pouteau E, Turner S, Aprikian O, et al. Time course and dynamics of adipose tissue development in obese and lean Zucker rat pups. Int J Obes (Lond). 2008;32:648-657.
42. Jung HR, Turner SM, Neese RA, Young SG, Hellerstein MK. Metabolic adaptations to dietary fat malabsorption in chylomicron-deficient mice. Biochem J. 1999;343(Pt 2):473-478.
43. Yu CY, Mayba O, Lee JV, et al. Genome-wide analysis of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in triglyceride homeostasis. PLoS One. 5:e15188.
44. Beysen C, Murphy EJ, McLaughlin T, et al. Whole-body glycolysis measured by the deuterated-glucose disposal test correlates highly with insulin resistance in vivo. Diabetes Care. 2007;30:1143-1149.
45. Long W, Wei L, Barrett EJ. Dexamethasone inhibits the stimulation of muscle protein synthesis and PHAS-I and p70 S6-kinase phosphorylation. Am J Physiol. 2001;280:E570-E575.
46. Louard RJ, Bhushan R, Gelfand RA, Barrett EJ, Sherwin RS. Glucocorticoids antagonize insulin's antiproteolytic action on skeletal muscle in humans. J Clin Endocrinol Metab. 1994;79:278-284.
47. Odedra BR, Bates PC, Millward DJ. Time course of the effect of catabolic doses of corticosterone on protein turnover in rat skeletal muscle and liver. Biochem J. 1983;214:617-627.
48. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology. 1992;130:3378-3386.
49. May RC, Kelly RA, Mitch WE. Metabolic acidosis stimulates protein degradation in rat muscle by a glucocorticoid-dependent mechanism. J Clin Invest. 1986;77:614-621.
50. Price SR, Du J, Bailey JL, Mitch WE. Molecular Mechanisms Regulating Protein Turnover in Muscle. Am J Kidney Dis. 2001;37: S112-S114.
51. Tiao G, Fagan J, Roegner V, et al. Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J Clin Invest. 1996;97:339-348.
52. Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitindependent proteolytic system in skeletal muscle during fasting. Am J Physiol. 1993;264:E668-E676.
53. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest. 1997;99:414-423.
54. Rogatsky I, Wang JC, Derynck MK, et al. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc Natl Acad Sci U S A. 2003;100:13845-13850.